Hans Lehrach

This inventor holds 15 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Alaeris Theranostics Gmbh, Charité – Universitätsmedizin Berlin. Active years: 2003-2018.

USPTO Granted Patents = 15 (Patent Applications = 12)

% Patents Active = 86.7

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 23)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 93(Granted Patents)

Location History:

14129 Berlin, DE (2003)
Berlin, DE (2003 - 2018)

Company Filing History:

12 out of 1,327

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

1 out of 1

Alaeris Theranostics Gmbh

patent

1 out of 283

Charité – Universitätsmedizin Berlin

National Public Health Institute

patents

6. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10041947 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2018-08-07),

2. 9880168 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2018-01-30),

3. 9631214 - Method for linking and characterising linked nucleic acids, E.G. antibody encoding nucleic acids, in a composition (2017-04-25),

4. 9540697 - Prostate cancer markers (2017-01-10),

5. 9335329 - Diagnostic prediction of rheumatoid arthritis and systemic lupus erythematosus (2016-05-10),

6. 9175336 - Method for differentiation of polynucleotide strands (2015-11-03),

7. 9052312 - Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment (2015-06-09),

8. 8999677 - Method for differentiation of polynucleotide strands (2015-04-07),

9. 7595199 - Method of detecting amyloid-like fibrils or protein aggregates (2009-09-29),

10. 7078191 - Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation (2006-07-18),

11. 7005008 - Reaction vessel (2006-02-28),

12. 6951928 - Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED) (2005-10-04),

13. 6905818 - Method for the identification and characterization of interacting molecules by automated interaction mating (2005-06-14),

14. 6664048 - Identification and characterization of interacting molecules (2003-12-16),

15. 6503710 - Mutation analysis using mass spectrometry (2003-01-07),

Title: The Innovations of Hans Lehrach

Introduction

Hans Lehrach is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of diagnostic methods and treatments. With a total of 15 patents to his name, Lehrach's work has had a profound impact on medical science.

Latest Patents

One of Lehrach's latest patents focuses on a biomarker for predicting responsiveness to anti-tumor necrosis factor alpha (TNF) treatment. This invention outlines a method for diagnosing individuals who are undergoing or are to undergo anti-TNF treatment. The method involves detecting immunoglobulins against specific biomarker proteins in bodily fluids or excrement. Based on this detection, individuals are classified as either responders or non-responders to the treatment. Additionally, the invention includes diagnostic kits that utilize these biomarker proteins to assess treatment responsiveness.

Career Highlights

Throughout his career, Hans Lehrach has been associated with notable institutions, including the Max Planck Society for the Advancement of Science. His work has been instrumental in advancing the understanding of biomarkers and their applications in personalized medicine.

Collaborations

Lehrach has collaborated with esteemed colleagues such as Erich Wanker and Zoltán Konthur. These partnerships have further enriched his research and innovations in the field.

Conclusion

Hans Lehrach's contributions to biotechnology and his innovative patents have significantly advanced medical diagnostics and treatment methodologies. His work continues to influence the field and improve patient outcomes.